Navigation Links
XTL Biopharmaceuticals Provides Update on Potential Strategic Alternatives
Date:1/28/2009

VALLEY COTTAGE, N.Y., Jan. 28 /PRNewswire-FirstCall/ -- XTL Biopharmaceuticals Ltd. (Nasdaq: XTLB, TASE: XTL) today announced an update to its December 8, 2008 press release regarding the Company's activities in seeking to acquire potential assets or to identify a company to merge into or with XTL.

The Company is currently evaluating several merger proposals that have been presented to it by both US and foreign-based companies who operate in and outside of the healthcare space. These discussions are preliminary in nature, and consequently, the timing of and ability to consummate such a transaction cannot be predicted at this time, and the Company may still decide that the distribution of its remaining assets to the shareholders in a liquidation offers the best possible alternative to the shareholders.

XTL has retained an investment banking firm to advise the Company in assessing these potential merger opportunities.

Cautionary Statement

Some of the statements included in this press release, particularly those anticipating future business prospects, may be forward-looking statements that involve a number of risks and uncertainties. For those statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. In particular, we may not be able to consummate a merger transaction with any of the potential merger partners due to certain conditions that are likely to be required by our potential merger partners and regulatory authorities. In addition, our remaining cash resources are scarce and we may be delisted from NASDAQ, both of which may further limit our ability to remain an attractive merger candidate. Any forward-looking statements set forth in this press release speak only as of the date of this press release. We do not intend to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. This press release and prior releases are available at http://www.xtlbio.com. The information in our website is not incorporated by reference into this press release and is included as an inactive textual reference only.


'/>"/>
SOURCE XTL Biopharmaceuticals Ltd.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Keryx Biopharmaceuticals to Present at the J.P. Morgan 27th Annual Healthcare Conference
2. Johnson & Johnson Completes Acquisition of Omrix Biopharmaceuticals, Inc.
3. XTL Biopharmaceuticals Implements Restructuring Plan
4. Nventa Biopharmaceuticals Announces Third Quarter 2008 Financial Results and Recent Corporate Highlights
5. Morria Biopharmaceuticals Plc Announces Positive Clinical Results for MRX-4 in its Phase II Clinical Study in Allergic Rhinitis Patients
6. Morria Biopharmaceuticals Plc to Present at the Rodman & Renshaw 10th Annual Healthcare Conference
7. Keryx Biopharmaceuticals Notified that Nasdaq Has Extended Minimum Bid Price Rule Compliance Period
8. Morria Biopharmaceuticals Plc Announces Results From its Pre-Clinical Screening of Novel Anti-Inflammatory Compounds
9. Nomad Bioscience: New Plant Biotechnology Company Founded to Focus on Biomaterials and Biopharmaceuticals
10. Bayer Broadens Its Manufacturing Basis for Biopharmaceuticals in Tobacco Plants
11. XTL Biopharmaceuticals Receives Notice of Non-Compliance with Nasdaq Marketplace Rule Due to Changes in Board Composition
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2017)... ... September 18, 2017 , ... Transportable biomass conversion facilities ... torrefied wood is the topic of a September 27 webinar hosted ... viability of transportable biomass conversion facilities for producing biochar, briquettes, and torrefied wood, ...
(Date:9/18/2017)... , Sept. 18, 2017   Montrium , a growing ... an exciting new partnership with a groundbreaking non-profit research organization, ... ... MDMA-assisted psychotherapy studies for PTSD ... has recently granted Breakthrough Therapy Designation to MDMA for the treatment ...
(Date:9/17/2017)... ... September 17, 2017 , ... GeneOne Life Science, Inc. announces ... Drug Safety (KMFDS) for an Investigational New Drug application for a Phase I/IIa ... (MERS-CoV). The study in Korea represents the second clinical trial for GLS-5300. ...
(Date:9/14/2017)... ... September 14, 2017 , ... ... Services, formally introduces its flexible scientist program (FSP)-- a flexible business approach ... The FSP, which combines SSCI’s extensive project-based analytical and solid-state chemistry services ...
Breaking Biology Technology:
(Date:4/3/2017)...  Data captured by IsoCode, IsoPlexis Corporation,s ... statistically significant association between the potency of ... objective response of cancer patients post-treatment. The ... cancer patients will respond to CAR-T cell ... to improve both pre-infusion potency testing and cell ...
(Date:3/30/2017)... 2017 Trends, opportunities and forecast in this ... technology (fingerprint, AFIS, iris recognition, facial recognition, hand geometry, ... end use industry (government and law enforcement, commercial and ... and others), and by region ( North America ... Asia Pacific , and the Rest of the ...
(Date:3/27/2017)... ROCKVILLE CENTRE, N.Y. , March 27, 2017 ... by Healthcare Information and Management Systems Society (HIMSS) ... Analytics Outpatient EMR Adoption Model sm . In ... top 12% of U.S. hospitals using an electronic ... recognized CHS for its high level of EMR ...
Breaking Biology News(10 mins):